Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
Elimor Brand-Schieber,1 Sagar Munjal,1 Rajesh Kumar,1 Anthony D Andre,2 Will Valladao,2 Margarita Ramirez2 1Dr. Reddy’s Laboratories Inc., Princeton, NJ, 2Interface Analysis Associates, Saratoga, CA, USA Background: Migraine pain relief is reported by more than 50% of patients who receive...
Enregistré dans:
Auteurs principaux: | Brand-Schieber E, Munjal S, Kumar R, Andre AD, Valladao W, Ramirez M |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a2eb8fb1d91640138c1c1af8a4b6abbc |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
par: Tepper SJ, et autres
Publié: (2018) -
Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience
par: Callis Duffin K, et autres
Publié: (2016) -
Development of an advanced injection time model for an autoinjector
par: Thueer T, et autres
Publié: (2018) -
Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population
par: Lange J, et autres
Publié: (2015) -
The effect of weight, body mass index, age, sex , and race on plasma concentrations of subcutaneous sumatriptan: a pooled analysis
par: Munjal S, et autres
Publié: (2016)